Hong Kong, Nov. 19 /PRNewswire-Asia/ -- China's leading high-tech healthcare group, Golden Meditech Company Limited ("Golden Meditech" or "the Group"; Stock Code: 0801.HK) is pleased to announce today that the Group's associate company China Cord Blood Corporation ("CCBC," NYSE: CO) has been listed on the New York Stock Exchange main board (NYSE) under the ticker symbol "CO" after a successful secondary offering. The shares of CCBC started trading at 9:30 am (Eastern Time) on November 19, 2009.

As of today, Golden Meditech holds 44% of CCBC. Based on the offering price of US$6.05 per share, our holding is valued at US$176 million.

As the first umbilical cord blood bank operator in China, CCBC pioneered the commercialization of cord blood storage services in 2003. Over the past six years, CCBC has developed into the largest cord blood bank operator in China in terms of geographical coverage, with exclusive operations in both Beijing and Guangdong Province. In addition, CCBC also owns cord blood bank operations in India, Indonesia, Singapore, the Philippines, Malaysia, China Hong Kong and Australia through an associate company, which makes CCBC the largest cord blood bank in the world in term of total addressable population, geographic coverage, and ethnic groups served.

Investors responded positively to this offering. CCBC issued 3.3 million ordinary shares and raised US$20 million dollars. The offering was handled by renowned investment banks Macquarie Bank and Roadman & Renshaw which are the co-sponsors and co-lead underwriters for this offering.

Mr. KAM Yuen, Chairman and CEO of Golden Meditech, said, "The successful listing of CCBC on the NYSE represents another successful investment that the Golden Meditech management team has made in China's healthcare industry over the past years. It not only signifies the Group's strong execution capability, but also unlocks the value of the underlying business for our shareholders."

Golden Meditech: Golden Meditech was listed on the Growth Enterprise Market of the Stock Exchange of Hong Kong Limited (HKEX) in December 2001, as the first hi-tech medical device enterprise that went public outside of the PRC. It was admitted to the main board in June 2009. During the past few years, thanks to its great efforts in innovation and market expansion, as well as its first-mover abilities in capturing the emerging market opportunities, Golden Meditech's medical devices, cord blood banking services and innovative natural herbal medicines have all established dominant positions in their own sectors. Going forward, Golden Meditech will continue its pursuit of becoming China's leading integrated medical group through organic growth, acquisitions and strategic investments.

    For more information, please contact:

    Investor Relations Division, Golden Meditech Company Limited
     Address: 48/F, Bank of China Tower, 1 Garden Road, Central, Hong Kong
     Tel:     +852-3605-8138
     Fax:     +852-3605-8181
     Email: ir@goldenmeditech.com

SOURCE Golden Meditech Company Limited

Back to top